Skip to main content
Savara Inc logo

Savara Inc — Investor Relations & Filings

Ticker · SVRA ISIN · US8051111016 LEI · 5493002JO0WM3YMJXG33 US Manufacturing
Filings indexed 1,005 across all filing types
Latest filing 2026-04-24 Annual Report
Country US United States of America
Listing US SVRA

About Savara Inc

https://savarapharma.com/

Savara Inc. is a clinical-stage biopharmaceutical company that develops therapies for rare respiratory diseases. The company's lead product candidate is molgramostim nebulizer solution, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). This candidate, which has the conditionally accepted trade name MOLBREEVI, is in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease. Savara has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for MOLBREEVI for this indication.

Recent filings

Filing Released Lang Actions
ARS - Savara Inc (0001160308) (Filer)
Annual Report
2026-04-24 English
4 - Savara Inc (0001160308) (Issuer)
Director's Dealing
2026-03-20 English
4 - SAVARA INC (0001160308) (Filer)
Director's Dealing
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-13 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-05 English
8-K Filing
Regulatory Filings
2026-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.